Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease

Journal of Infection

Volumn 58, Issue 6, 2009, Pages 417-424

  Molinos, L ^a   Clemente, M G ^b   Miranda, B ^a   Alvarez, C ^a   del Busto, B ^c   Cocina, B R ^d   Alvarez, F ^e   Gorostidi, J ^f   Orejas, C ^g  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL ÁLVAREZ BUYLLA   (Spain)

^c HOSPITAL DE JOVE   (Spain)

^d HOSPITAL SEVERO OCHOA   (Spain)

^e HOSPITAL SAN AGUSTÍN   (Spain)

^f Hospital de Jarrio   (Spain)

^g Hospital Grande Cobian   (Spain)

Author keywords

Chronic obstructive pulmonary disease; Community acquired pneumonia; Mortality

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CEFUROXIME AXETIL; CEPHALOSPORIN; CIPROFLOXACIN; CLINDAMYCIN; CORTICOSTEROID; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM;

AGED; ARTERIAL OXYGEN TENSION; ARTICLE; BLOOD CULTURE; BREATHING RATE; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CONTROLLED STUDY; FEMALE; FEVER; HUMAN; HYPERCAPNIA; HYPOXEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; OXYGEN THERAPY; PLEURA EFFUSION; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR; SEPTIC SHOCK; SPUTUM CULTURE; SPUTUM VISCOSITY;

AGED; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PNEUMONIA; PNEUMONIA, BACTERIAL; PNEUMONIA, VIRAL; PROSPECTIVE STUDIES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SPIROMETRY;

EID: 67349270074     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2009.03.003     Document Type: Article

References (30)

1. Sobradillo V., Miravitlles M., Gabriel R., Jimenez-Ruiz C., Villasante C., Masa J.F., et al. Geographic variations in prevalence and underdiagnosis of COPD. Results of the IBERPOC multicentre epidemiological study. Chest 118 (2000) 981-989
2. BTS guidelines for the management of community-acquired pneumonia in adults. Thorax 56 Suppl. 4 (2001) 1-64
3. Almirall J., Bolíbar I., Serra-Prat M., Roig J., Hospital I., and Carandell E. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J 31 (2008) 1274-1284
4. Falguera M., Martín M., Ruiz-González A., Pifarré R., and García M. Community-acquired pneumonia as the initial manifestation of serious underlying diseases. Am J Med 118 (2005) 378-383
5. Torres A., Dorca J., Zalacain R., Bello S., El-Ebiary M., Molinos L., et al. Community-acquired pneumonia in chronic obstructive pulmonary disease: a Spanish multicenter study. Am J Respir Crit Care Med 154 (1996) 1456-1461
6. Merino-Sánchez M., Alfageme Michavila I., Reyes-Nuñez N., and Lima-Alvarez J. Evaluación pronóstica de las neumonías en pacientes con EPOC. Arch Bronconeumol 41 (2005) 607-611
7. Ruiz de Oña J.M., Gómez Fernández M., Celdrán J., and Puente-Maestu L. Neumonía en el paciente con enfermedad pulmonar obstructiva crónica. Niveles de gravedad y clases de riesgo. Arch Bronconeumol 39 (2003) 101-105
8. Pifarre R., Falguera M., Vicente-de-Vera C., and Nogués A. Characteristics of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. Respir Med 101 10 (2007) 2139-2144
9. Restrepo M.I., Mortensen E.M., Pugh J.A., and Anzueto A. COPD is associated with increased mortality in patients with community-acquired pneumonia. Eur Respir J 28 (2006) 346-351
10. Rello J., Rodriguez A., Torres A., Roig J., Solé-Violan, Garnacho-Montero J., et al. Implications of COPD in patients admitted to the intensive care unit by community-acquired pneumonia. Eur Respir J 27 (2006) 1210-1216
11. Pinto-Plata V.M., Müllerova H., Toso J.F., Feudjo-Tepie M., Soriano J.B., Vessey R.S., et al. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 61 (2006) 23-28
12. Garcia Vazquez E., Martinez J.A., Mensa J., Sánchez F., Marcos M.A., de Roux A., et al. C-reactive protein levels in community-acquired pneumonia. Eur Respir J 21 (2003) 702-705
13. Fang G.D., Fine M., Orloff J., Arisumi D., Yu V.L., Kapoor W., et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine 69 (1990) 307-316
14. American Thoracic Society/European Respiratory Society Task Force. Standards for the diagnosis and management of patients with COPD. [Internet]. Version 1.2 (2004), American Thoracic Society, New York. http://www.thoracic.org/go/copd Available from:[accessed 08.09.05]
15. Fine M.J., Auble T.E., Yealy D.M., Hanusa B.H., Weissfeld L.A., Singer D.E., et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 336 (1997) 243-250
16. Boersma W.G., Sportel J.H., Löwenberg A., and Koëter G.H. High prevalence of obstructive airways disease in hospitalized patients with community-acquired pneumonia: comparison of four etiologies. Clin Pulm Med 12 (2005) 291-296
17. Mandel L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 (2007) S27-S72
18. Sobradillo V., Ansola P., Baranda F., and Corral C. Q fever pneumonia: a review of 164 community-acquired cases in the Basque country. Eur Respir J 2 (1989) 263-266
19. Marrie T.J., and Shariatzadeh M.R. Community-acquired pneumonia requiring admission to an intensive care unit. Medicine 86 (2007) 103-111
20. Oga T., Nishimura K., Tsukino M., Sunumo S., and Hajiro T. Analysis of the factors related to mortality in chronic obstructive pulmonary disease. Role of exercise capacity and health status. Am J Respir Crit Care Med 167 (2003) 544-549
21. Lim W.S., Lewis S., and Macfarlane J.T. Severity prediction rules in community-acquired pneumonia: a validation study. Thorax 55 (2000) 219-223
22. Sin D.D., Man S.F., and Marrie T.J. Arterial carbon dioxide tension on admission as a marker of in-hospital mortality in community-acquired pneumonia. Am J Med 118 (2005) 145-150
23. Confalonieri M., Urbino R., Potena A., Piattella M., Parigi P., Puccio G., et al. Hydrocortisone infusion for severe community-acquired pneumonia: a preliminary randomized study. Am J Respir Crit Care Med 171 (2005) 242-248
24. Garcia-Vidal C., Calbo E., Pascual V., Ferrer C., Quintana S., and Garau J. Effects of systemic steroids in patients with severe community-acquired pneumonia. Eur Respir J 30 (2007) 951-956
25. Waterer G.W. Monotherapy versus combination antimicrobial therapy for pneumococcal pneumonia. Curr Opin Infect Dis 18 (2005) 157-163
26. Harbarth S., Nobre V., and Pittet D. Does antibiotic selection impact patient outcome?. Clin Infect Dis 44 (2007) 87-93
27. Anthonisen N.R., Marfreda J., Warren C.P.W., Hershfield E.S., Harding G.K., and Nelson N.A. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106 (1987) 196-204
28. Ernst P., Gonzalez A.V., Brassard P., and Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 176 (2007) 162-166
29. Woodhead M. Inhaled corticosteroids cause pneumonia or do they?. Am J Respir Crit Care Med 176 (2007) 111-112
30. Torres A., and Menéndez R. Mortality in COPD patients with community-acquired pneumonia: who is the third partner?. Eur Respir J 28 (2006) 262-263